Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Jan 5;30(1):12-13.
doi: 10.1016/j.ymthe.2021.12.004. Epub 2021 Dec 11.

Advanced therapeutic strategy for hereditary neuromuscular diseases

Wuh-Liang Hwu  1 , Shin-Ichi Muramatsu  2 , Yin-Hsiu Chien  3 , Barry J Byrne  4
Affiliations
Comment

Advanced therapeutic strategy for hereditary neuromuscular diseases

Wuh-Liang Hwu et al. Mol Ther. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Declaration of interests W.-L.H. licenses a gene therapy to PTC therapeutics and receives honoraria and research grants from PTC. S.-I.M. owns equity in Gene Therapy Research Institution, Co., Ltd (GTRI), and receives a research grant from the GTRI. In addition, S.-I.M. is an advisory to PTC therapeutics. He has also received honoraria from PTC therapeutics and Novartis. B.J.B. reports receiving personal fees from Sanofi Genzyme for membership in the Pompe Registry Advisory Board. Y.-H.C. received honoraria from Sanofi Genzyme and Novartis and is a member in the Pompe Registry Advisory Board and also received research grants from Sanofi Genzyme.

Comment on

References

    1. Weiß C., Ziegler A., Becker L.L., Johannsen J., Brennenstuhl H., Schreiber G., Flotats-Bastardas M., Stoltenburg C., Hartmann H Illsinger S., et al. Gene replacement therapy with onasemnogene abeparvovec in children with spinal muscular atrophy aged 24 months or younger and bodyweight up to 15 kg: an observational cohort study. Lancet Child Adolesc. Health. 2021;5 doi: 10.1016/S2352-4642(21)00287-X. - DOI - PubMed
    1. Kolb S.J., Kissel J.T. Spinal muscular atrophy: a timely review. Arch. Neurol. 2011;68:979–984. - PMC - PubMed
    1. Mercuri E., Muntoni F., Baranello G., Masson R., Boespflug-Tanguy O., Bruno C., Corti S., Daron A., Deconinck N., et al. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial. Lancet Neurol. 2021;20:832–841. - PubMed
    1. Ditters I.A.M., Huidekoper H.H., Kruijshaar M.E., Rizopoulos D., Hahn A., Mongini T.E., Labarthe F., Tardieu M., Chabrol B., Brassier A., et al. Effect of alglucosidase alfa dosage on survival and walking ability in patients with classic infantile Pompe disease: a study of the European Pompe Consortium. Lancet Child Adolesc. Health. 2021;5 doi: 10.1016/S2352-4642(21)00308-4. - DOI - PubMed
    1. Chien Y.H., Lee N.C., Thurberg B.L., Chiang S.C., Zhang X.K., Keutzer J., Huang A.C., Wu M.H., Huang P.H., Tsai F.J., et al. Pompe disease in infants: improving the prognosis by newborn screening and early treatment. Pediatrics. 2009;124:e1116–e1125. - PubMed

MeSH terms